What blood tests matter before stopping GLP-1 medication?

Why blood tests before stopping matter

Stopping GLP-1 medication is not just about appetite and weight. These drugs affect glucose metabolism, blood pressure, lipids, kidney function, and liver enzymes. A blood test snapshot before stopping gives you a baseline against which to measure change — and may reveal findings that alter whether or when you stop, or what monitoring you need after.

The right panel depends on your indication, comorbidities, and medication list. There is no universal pre-stopping blood test requirement — but there are tests that are clinically useful for most people and essential for some.

HbA1c: essential if you have diabetes or pre-diabetes

GLP-1 agents lower HbA1c through multiple mechanisms. Stopping will worsen glucose control to some degree in anyone with impaired glucose metabolism. Knowing your HbA1c before stopping gives your clinician the information to decide whether additional glucose management is needed and sets a baseline for monitoring in the weeks after. If your HbA1c is well-controlled on GLP-1 medication, stopping without an alternative glucose plan in place is clinically incomplete. [1]

If you have pre-diabetes rather than established type 2 diabetes, the HbA1c still matters — weight gain after stopping may push glucose back toward the diabetic threshold.

Fasting lipids: often overlooked but important

GLP-1-assisted weight loss typically improves lipid profiles — LDL, triglycerides, and HDL all tend to move favourably. [2] These gains reverse with weight regain. A lipid panel before stopping records where you are while the medication is working — if stopping leads to significant weight regain and lipid deterioration, having a pre-stopping baseline means the deterioration is visible and actionable rather than ambiguous.

This is particularly relevant if cardiovascular risk is part of the clinical picture, or if lipid-lowering medication was reviewed (reduced or stopped) during the weight loss phase.

Kidney function: eGFR and creatinine

GLP-1 agents have been shown to have renoprotective effects in patients with chronic kidney disease (the FLOW trial demonstrated this for semaglutide). [3] In patients with established kidney disease, stopping GLP-1 medication removes this protection. Knowing current eGFR and creatinine before stopping allows monitoring of any kidney function change after cessation — which in a patient with CKD may be clinically significant.

For most patients without known kidney disease, a baseline creatinine is useful principally to rule out occult impairment that might affect other medication choices.

Liver enzymes: ALT and AST

GLP-1 agents improve metabolic dysfunction-associated steatohepatitis (MASH) and generally reduce liver enzymes in patients with fatty liver disease. [4] If you have elevated liver enzymes at baseline and these improved during GLP-1 treatment, a pre-stopping measurement records the improvement. Reversal after stopping — if weight is regained — is predictable and worth tracking.

What blood tests alone cannot tell you

Blood tests are a snapshot, not a monitoring system. The most important pre-stopping assessment for most patients is blood pressure — checked sitting and standing, not just at a single point. This is particularly true if you are on antihypertensives, where the consequences of getting the medication adjustment wrong are immediate (dizziness, falls) rather than deferred (as with lipids or HbA1c). Read more in blood pressure after weight loss.

A Clinical Data Review interprets your existing results in the context of your medication list and stopping plan — it does not require starting from scratch.

Timing: when to test

Ideally, blood tests before stopping should be taken while the medication is still active — reflecting the best metabolic state — not the day before the last dose when levels are near a trough. This gives the clearest picture of what the medication achieved and what is at risk of reversing. Allow four to eight weeks after stopping before repeating, which gives enough time for meaningful change to show.